Last reviewed · How we verify
Hyperpolarized 13C,15N2-urea
Hyperpolarized 13C,15N2-urea is a diagnostic imaging agent that uses hyperpolarized carbon-13 to enhance the visibility of metabolic processes in the body.
Hyperpolarized 13C,15N2-urea is a diagnostic imaging agent that uses hyperpolarized carbon-13 to enhance the visibility of metabolic processes in the body. Used for Assessment of tumor metabolism in patients with cancer.
At a glance
| Generic name | Hyperpolarized 13C,15N2-urea |
|---|---|
| Also known as | Urea C-13, C13 Urea, HP 13C, 15N2 |
| Sponsor | Ivan de Kouchkovsky, MD |
| Drug class | Diagnostic imaging agent |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
This agent works by exploiting the unique properties of hyperpolarized carbon-13 to create high-contrast images of metabolic activity in tissues. This allows for the non-invasive assessment of various physiological processes, such as glucose metabolism in cancer cells.
Approved indications
- Assessment of tumor metabolism in patients with cancer
Common side effects
Key clinical trials
- Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors (PHASE2)
- Pilot Study of (MR) Imaging with Pyruvate (13C) to Detect High Grade Prostate Cancer (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hyperpolarized 13C,15N2-urea CI brief — competitive landscape report
- Hyperpolarized 13C,15N2-urea updates RSS · CI watch RSS
- Ivan de Kouchkovsky, MD portfolio CI